Inception to Anchor Company: The Fusion Origin Story

04 Jun 2024

Fusion acquired by AstraZeneca for $2.4 USD

View Full Article

Latest

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis

Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy

Zynext Ventures Invests in Feldan Therapeutics to Drive Innovation in Intracellular Drug Delivery

All Articles

Genesys Capital is closing its largest fund to date – Genesys Ventures IV LP

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis

Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy

Zynext Ventures Invests in Feldan Therapeutics to Drive Innovation in Intracellular Drug Delivery